133 related articles for article (PubMed ID: 26515125)
1. Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
Amaral C; Lopes A; Varela CL; da Silva ET; Roleira FM; Correia-da-Silva G; Teixeira N
Int J Biochem Cell Biol; 2015 Dec; 69():183-95. PubMed ID: 26515125
[TBL] [Abstract][Full Text] [Related]
2. Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
Varela CL; Amaral C; Tavares da Silva E; Lopes A; Correia-da-Silva G; Carvalho RA; Costa SC; Roleira FM; Teixeira N
Eur J Med Chem; 2014 Nov; 87():336-45. PubMed ID: 25277066
[TBL] [Abstract][Full Text] [Related]
3. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis and autophagy in breast cancer cells following exemestane treatment.
Amaral C; Borges M; Melo S; da Silva ET; Correia-da-Silva G; Teixeira N
PLoS One; 2012; 7(8):e42398. PubMed ID: 22912703
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
[TBL] [Abstract][Full Text] [Related]
6. Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
Amaral C; Augusto TV; Tavares-da-Silva E; Roleira FMF; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2018 Oct; 183():51-61. PubMed ID: 29791862
[TBL] [Abstract][Full Text] [Related]
7. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
8. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
[TBL] [Abstract][Full Text] [Related]
9. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
[TBL] [Abstract][Full Text] [Related]
10. Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Chen D; Hackl W; Ortmann O; Treeck O
Anticancer Drugs; 2004 Jan; 15(1):55-61. PubMed ID: 15090744
[TBL] [Abstract][Full Text] [Related]
11. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione).
Buzzetti F; Di Salle E; Longo A; Briatico G
Steroids; 1993 Nov; 58(11):527-32. PubMed ID: 8273115
[TBL] [Abstract][Full Text] [Related]
13. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
14. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
15. Exemestane: treatment of breast cancer with selective inactivation of aromatase.
Higa GM
Am J Health Syst Pharm; 2002 Nov; 59(22):2194-2201; quiz 2202-4. PubMed ID: 12455303
[TBL] [Abstract][Full Text] [Related]
16. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Bertelli G; Gangadhara S
Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
[TBL] [Abstract][Full Text] [Related]
17. Microbial-catalysed derivatization of anti-cancer drug exemestane and cytotoxicity of resulting metabolites against human breast adenocarcinoma cell line (MCF-7) in vitro.
Baydoun S; Wahab AT; Bano S; Imad R; Choudhary MI
Steroids; 2016 Nov; 115():67-74. PubMed ID: 27521799
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effect of exemestane in lung cancer cells.
Koutras A; Giannopoulou E; Kritikou I; Antonacopoulou A; Evans TR; Papavassiliou AG; Kalofonos H
Mol Cancer; 2009 Nov; 8():109. PubMed ID: 19930708
[TBL] [Abstract][Full Text] [Related]
19. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells.
Shen Y; Du Y; Zhang Y; Pan Y
Mol Med Rep; 2015 Jul; 12(1):456-62. PubMed ID: 25738757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
